Effective March 1, 2021, Ellen van den Bogaard has been appointed professor of Innovative Experimental and Translational Dermatology at Radboud university medical center/Radboud University. She will focus on the development of scientific skin models to elucidate mechanisms behind chronic skin diseases such as psoriasis and eczema.
Van den Bogaard's research focuses on the development of natural tissue culture models (organoids, mini-organs) of human body cells, which mimic the construction and function of the skin. Van den Bogaard will specifically focus on refining and implementing these skin models with new research techniques, so that they become valuable for the individual patient with a chronic inflammatory skin disease, like psoriasis or atopic eczema.
Three-dimensional models of the skin
Ellen H.J. van den Bogaard (1984, Wijchen) studied Biomedical Sciences at Radboud University in Nijmegen. She obtained her PhD cum laude in 2014 on her thesis ‘From skin development to disease pathogenesis and therapeutics - The power of 3D skin models’. During her PhD, she developed mini-organs as models for human skin, which have enabled important discoveries in the field of risk factors for disease and biological functions of proteins in the skin. For this, she was awarded the Willy van Heumen Prize in 2015 by the Stimulation Fund for Alternatives to Experimental Animals.
Better treatment for skin diseases
After her PhD, Van den Bogaard conducted research at Pennsylvania State University, after which she started her own line of research at the Department of Dermatology at Radboud university medical center in 2015 with a Veni grant from the Dutch organization for science NWO. In 2018, Van den Bogaard was appointed head of the Laboratory of Experimental Dermatology. Here she combines her knowledge of three-dimensional skin models with molecular tissue analyses to study the skin of individual patients. By better understanding how certain risk factors underlie skin diseases, she hopes to discover new ways for better treatments in the future.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros15 June 2021
Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells.read more
Human microbiome could shed light on higher morbidity rate in minoritized populations The link between environmental inequities and disease may lie in the gut15 June 2021
A study published in PNAS is the first to explicitly address the gut microbiome as a pathway to understanding how environmental inequities could lead to health disparities.read more
New ultra-high field MRI system available for Radboudumc and Radboud University10 June 2021
Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up.read more
On the prevalence of cerebral amyloid angiopathy a systematic review and meta-analysis10 June 2021
Published in ‘Alzheimers and Dementia’, researchers at Radboudumc performed a systematic review and meta-analysis on the prevalence of Cerebral Amyloid Angiopathy. They scrutinized and analyzed 170 publications, comprising publications using either a neuroimaging or a neuropathological approach.read more
Retina-on-chip modeling and treating eye diseases in a dish10 June 2021
Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.read more
New method to prevent ovarian cancer increases quality of life8 June 2021
Researchers at Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after fallopian tube removal with delayed ovarian removal to prevent ovarian cancer.read more